Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma

Status: Active

Description

This pilot phase I trial studies the side effects and best dose of everolimus and to see how well it works when given together with nelarabine, cyclophosphamide, and etoposide phosphate in treating patients with T cell lymphoblastic leukemia or lymphoma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as everolimus, nelarabine, cyclophosphamide, and etoposide phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Eligibility Criteria

Inclusion Criteria

  • Patients must have relapsed (first or greater relapse) or refractory T-cell acute lymphoblastic leukemia (T-ALL) with: * Relapsed T-ALL with an M2 (blasts >= 5 to =< 25%) or M3 (> 25% blasts) marrow with or without an extramedullary site of relapse; including central nervous system (CNS) 2 OR * Refractory disease after induction failure of newly diagnosed patients OR no more than two more cycles of therapy OR * Refractory disease with no more than one prior salvage attempt following the current relapse
  • Patients must have relapsed (first or greater relapse) or refractory lymphoma with: * Lymphoblastic lymphoma or peripheral T-cell lymphoma * Histologic verification of disease at original diagnosis or subsequent relapse * Evaluable or measurable disease documented by clinical or radiographic criteria or bone marrow disease present at study entry * Patient may have CNS 2 status if other sites of leukemia or lymphoma involvement are present
  • Patients must have a Karnofsky >= 50% for subjects > 16 years of age and Lansky score >= 50 for subjects =< 16 years of age * Note: Subjects who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
  • Patients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study
  • Patients who relapse on therapy other than standard ALL maintenance therapy must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study * Cytotoxic chemotherapy: At least 7 days must have elapsed since the completion of cytotoxic therapy (other than standard ALL maintenance therapy) with the exception of hydroxyurea, which is permitted up to 24 hours prior to the start of protocol therapy * Nitrosoureas: At least 42 days must have elapsed since administration of nitrosoureas * Hematopoietic growth factors: At least 14 days after the last dose of long acting hematopoietic growth factor (e.g. Neulasta) or 7 days for short acting growth factor (e.g. Neupogen) * Radiation: At least 84 days must have elapsed since administration of craniospinal, hemipelvic or other radiation therapy to more than 25% of the bone marrow containing spaces; at least 42 days must have elapsed if other substantial marrow radiation has been given * Nelarabine prior therapy: Patients who have previously been treated with nelarabine are eligible, however if they have previously received a regimen of nelarabine, cyclophosphamide and etoposide, they are not eligible * Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair * Immunotherapy: At least 42 days after the completion of any type of immunotherapy (e.g. tumor vaccines or chimeric antigen receptor T cell (CART) therapy * Monoclonal antibodies: Monoclonal antibodies: At least 3 half-lives of the antibody must have elapsed after the last dose of a monoclonal antibody * Stem cell infusion: No evidence of active graft versus (vs.) host disease and at least 84 days must have elapsed after transplant or stem cell infusion * Study specific limitations on prior therapy: Patient may not have previously received therapy with an mTOR inhibitor * Prior intrathecal therapy: Patients may be enrolled on study regardless of the timing of prior intrathecal therapy; however, they MAY NOT BEGIN TREATMENT ON THIS PROTOCOL UNTIL A MINIMUM OF 7 DAYS HAS ELAPSED SINCE PRIOR INTRATHECAL THERAPY
  • Patients should not be known to be refractory to red blood cell or platelet transfusions
  • Blood counts are not required to be normal prior to enrollment on trial
  • Total bilirubin (sum of conjugated + unconjugated) =< 1.5 x institutional upper limit of normal for age
  • Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) and serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) must be =< 3 x institutional upper limit of normal (grade 1 or less per Common Terminology Criteria for Adverse Events [CTCAE] 5.0)
  • Gamma-glutamyl transpeptidase (GGT) must be =< 2.5 x institutional upper limit of normal (grade 1 or less per CTCAE 5.0)
  • Serum albumin >= 2 g/dL
  • The hepatic requirements may be waived for patients with grade 1 or 2 elevations of hepatic transaminases clearly due to leukemic infiltration after consultation with a study chair/co-chair
  • Serum creatinine =< 1.5 x upper limit of normal (ULN) for age; if the serum creatinine is above these values, the calculated creatinine clearance or radioisotope glomerular filtration rate (GFR) must be >= 70 mL/min/1.73 m^2
  • Shortening fraction of >= 27% by echocardiogram, OR
  • Ejection fraction of >= 50% by gated radionuclide study/echocardiogram
  • Pulse oximetry > 94% on room air
  • No evidence of dyspnea at rest and no exercise intolerance
  • Baseline chest x-ray with no evidence of active infectious disease or pneumonitis
  • Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment
  • Female patients with infants must agree not to breastfeed their infants while on the study
  • Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study; males should not get females pregnant for 90 days after last dose of everolimus
  • Fasting or random blood glucose within the upper limits of normal for age
  • If random blood glucose is above upper limits for age, a fasting blood glucose can be obtained and must be within normal limits for age
  • Fasting or non-fasting serum triglyceride level =< 300 mg/dL and serum cholesterol level =< 300 mg/dL
  • Patients and/or their parents or legal guardians must be capable of understanding the investigational nature, potential risks and benefits of the study; all patients and/or their parents or legal guardians must sign a written informed consent

Exclusion Criteria

  • Diagnosis * Patients with CNS3 disease * Patients with isolated extra-medullary relapse involving only sanctuary sites (e.g. testicular relapse) but patients with extramedullary disease involving nodal or other non-sanctuary sites are eligible * Patients with isolated testicular relapse * Patients with Philadelphia chromosome positive (Ph+) T-ALL/T-LLy * Patients with Down syndrome * Patients with pre-existing grade 2 (or higher) peripheral motor or sensory neurotoxicity per CTCAE 5.0 * Patients with a history of prior veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) or findings consistent with a diagnosis of VOD/SOS, defined as: conjugated serum bilirubin > 1.4 mg/dL AND unexplained weight gain greater than 10% of baseline weight or ascites AND hepatomegaly or right upper quadrant pain without another explanation, OR reversal of portal vein flow on ultrasound, OR pathological confirmation of VOD on liver biopsy
  • Infection Criteria * Positive blood culture within 48 hours of study enrollment * Fever above 38.2 within 48 hours of study enrollment with clinical signs of infection; fever that is determined to be due to tumor burden is allowed if patients have documented negative blood cultures for at least 48 hours prior to enrollment and no concurrent signs or symptoms of active infection or hemodynamic instability * Active fungal, viral, bacterial, or protozoal infection requiring IV treatment; chronic prophylaxis therapy to prevent infections is allowed
  • Skin condition * Patients with pre-existing grade 1 or higher ulcerations, fistulas, mucosal lesions, or skin barrier breakdown
  • Concomitant medications * Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; corticosteroids must be held for 24 hours prior to initiation of study therapy * Investigational drugs: Patients who are currently receiving another investigational drug are not eligible; the definition of “investigational” for use in this protocol means any drug that is not licensed by the Food and Drug Administration (FDA) * Anti-cancer agents: Patients who are currently receiving or may receive while on therapy, other anti-cancer agents, radiation therapy or immunotherapy are not eligible (except leukemia patients who relapsed on maintenance therapy or patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy); intrathecal therapy may be given up to one week prior to initiation of study treatment * Anti-graft versus host disease (GVHD) or agents to prevent organ rejection post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial; at least 3 half-lives must have elapsed after the last dose of GVHD meds * Angiotensin-converting enzyme (ACE) inhibitors: Patients who are currently receiving ACE inhibitors are not eligible due to the development of angioneurotic edema-type reactions in some subjects who received concurrent treatment with everolimus + ACE inhibitors; at least 3 half-lives must have elapsed after the last dose of ACE inhibitors * Anti-convulsants: Patients who are currently receiving CYP3A4/PgP enzyme inducing anticonvulsants (e.g. phenytoin, phenobarbitol, or carbamazepine) are not eligible; stabilizing on a non-hepatic inducing metabolizing anti-convulsant (ie: gabapentin or levetiracetam) prior to study entry is acceptable; at least 3 half-lives must have elapsed after the last dose of enzyme inducing anti-convulsants * Inhibitors of everolimus metabolism: Patients receiving treatment with azoles such as fluconazole or voriconazole which are potent inhibitors of everolimus metabolism; at least 3 half-lives must have elapsed after the last dose of azoles
  • Patients with significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance with protocol treatment or required observations, interfere with consent, study participation, follow up, or interpretation of study results

Locations & Contacts

Georgia

Atlanta
Children's Healthcare of Atlanta - Egleston
Status: Active
Contact: Himalee Shreekant Sabnis
Phone: 404-727-3285
Email: hsabnis@emory.edu

Texas

Houston
Texas Children's Hospital
Status: Active
Contact: Eric Stephen Schafer
Email: esschafe@txch.org

Trial Objectives and Outline

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) and describe the dose-limiting toxicity (DLT) of everolimus when given in combination with nelarabine, etoposide phosphate (etoposide) and cyclophosphamide to children with bone marrow relapse of T cell acute lymphoblastic leukemia (T-ALL) or relapsed T cell lymphoblastic lymphoma (T-LL).

SECONDARY OBJECTIVES:

I. To determine the pharmacokinetics of everolimus when given in combination with nelarabine, cyclophosphamide and etoposide.

II. To describe changes in phosphoprotein (pAkt and p4EBP1) and Mer expression at time points pre- and post everolimus therapy in peripheral blood mono-nuclear cells (PBMCs) and bone marrow.

III. To determine the response rate as defined by the ability to achieve complete remission (CR) after 1 and 2 courses of this therapy in children with bone marrow relapse of T-ALL or relapsed T cell lymphoblastic lymphoma (T-LLy).

IV. For patients that proceed to allogeneic stem cell transplantation, to determine the time from start of study treatment to transplant in patients with bone marrow relapse of T-ALL or relapsed T-LLy.

OUTLINE: This is a dose-escalation study of everolimus.

Patients receive everolimus orally (PO) once daily (QD) on days 1-28, nelarabine intravenously (IV) over 60 minutes on days 1-5, etoposide phosphate IV over 1 hour on days 1-5, and cyclophosphamide IV over 30-60 minutes on days 1-5. Patients may also receive methotrexate intrathecally (IT), therapeutic hydrocortisone IT, and cytarabine IT between days 29-36. Patients with stable disease or with partial/complete response after course 1 may receive a second course.

Trial Phase & Type

Trial Phase

Phase I

Trial Type

Treatment

Lead Organization

Lead Organization
Children's Healthcare of Atlanta - Egleston

Principal Investigator
Himalee Shreekant Sabnis

Trial IDs

Primary ID AflacLL1602
Secondary IDs NCI-2017-01717, IRB00095500
Clinicaltrials.gov ID NCT03328104